Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD

Alar’s ketamine-based drug mitigates certain adverse events, which could eliminate the need for post-dose monitoring.The post Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD appeared first on Clinical Trials Arena.

Alar reports positive phase 1 results for long-acting ketamine therapy

TAICHUNG, April 6, 2026 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced the positive results from its phase 1 clinical study of ALA-3000, a proprietary long-acting, sustained-release ketamine injection for treatment-resistant depression (TRD). This randomized, double-blind, placebo-controlled, multiple-dose first-in-human…

Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. TAICHUNG, April 6, 2026 /PRNewswire/ — Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announ…